Forty-seven patients with solid tumors were treated on a phase I study of menogaril administered by mouth once per week. Nausea and vomiting were excessive at weekly doses of 350 and 450 mg/m2/week but were tolerable and controlled reasonably well by antiemetics at lower doses. There appeared to be
Phase I study of tauromustine administered in a weekly schedule
✍ Scribed by Gjedde, Susanne B.; Mouridsen, Henning T.; L-Madsen, Ebbe; Jensen, Niels V.; Blomquist, Erik; Bergh, Jonas; Söderberg, Martin; Wählby, Svante
- Book ID
- 123088024
- Publisher
- Elsevier Science
- Year
- 1993
- Tongue
- English
- Weight
- 245 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This phase I study was conducted to reevaluate the dose-limiting toxicities, maximum tolerated (MTD) and recommended phase II doses of oral NMF administered on a three times weekly schedule for 4 out of every 6 weeks. This schedule was based on the observation that prolonged administration of NMF wa
Maytansine, a new ansa macrolide antitumor antibiotic, was administered to a total of 107 patients in a Phase 1-11 study. Dose-limiting toxic reactions which occurred at 0.75-1.0 mg/M' in both Phase I and I1 were neurologic and consisted primarily of lethargylweakness (a debilitation syndrome) and p